C. Mamot

发表

Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08.

P. Neven, K. Zaman, R. Winterhalder, 2015, European journal of cancer.

Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo.

C. Mamot, John W. Park, D. Drummond, 2005, Cancer research.

Targeting Tumor-Associated Endothelial Cells: Anti-VEGFR2 Immunoliposomes Mediate Tumor Vessel Disruption and Inhibit Tumor Growth

Andreas Wicki, Gerhard Christofori, Richard Herrmann, 2011, Clinical Cancer Research.

Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain

Ryuta Saito, Mitchel S. Berger, Krystof S. Bankiewicz, 2005, Experimental Neurology.

Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.

K. Nackaerts, O. Riesterer, R. Stahel, 2015, The Lancet. Oncology.

Extensive Distribution of Liposomes in Rodent Brains and Brain Tumors Following Convection-Enhanced Delivery

M. Berger, C. Mamot, John W. Park, 2004, Journal of Neuro-Oncology.

In vivo Multiple Anticancer Drugs Immunoliposomes Significantly Enhance the Efficacy of Targeted − Epidermal Growth Factor Receptor

C. Mamot, John W. Park, D. Drummond, 2005 .

Epidermal Growth Factor Receptor (EGFR)-targeted Immunoliposomes Mediate Specific and Efficient Drug Delivery to EGFR- and EGFRvIII-overexpressing Tumor Cells1

C. Mamot, John W. Park, J. Marks, 2003 .

Epidermal Growth Factor Receptor ( EGFR )-targeted Immunoliposomes Mediate Specific and Efficient Drug Delivery to EGFR-and EGFRvIII-overexpressing Tumor Cells 1

C. Mamot, John W. Park, J. Marks, 2003 .

Drug Conjugates Such as Antibody Drug Conjugates (ADCs), Immunotoxins and Immunoliposomes Challenge Daily Clinical Practice

C. Mamot, W. Janthur, N. Cantoni, 2012, International journal of molecular sciences.

A phase I study of doxorubicin-loaded anti-EGFR immunoliposomes in patients with advanced solid tumors.

L. Bubendorf, R. Herrmann, C. Mamot, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells

R. Herrmann, C. Mamot, C. Rochlitz, 2006, Journal of drug targeting.

Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells

R. Herrmann, C. Mamot, C. Rochlitz, 2012, Journal of drug targeting.

Large-scale manufacturing of GMP-compliant anti-EGFR targeted nanocarriers: production of doxorubicin-loaded anti-EGFR-immunoliposomes for a first-in-man clinical trial.

C. Mamot, C. Rochlitz, A. Wicki, 2015, International journal of pharmaceutics.

Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07).

C. Mamot, G. Martinelli, S. Dirnhofer, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08).

C. Mamot, R. Cathomas, P. Fustier, 2013, Clinical lung cancer.

Infrequent mutation of the tumour-suppressor gene Smad4 in early-stage colorectal cancer

R. Herrmann, C. Mamot, C. Rochlitz, 2003, British Journal of Cancer.

Distribution of Liposomes into Brain and Rat Brain Tumor Models by Convection-Enhanced Delivery Monitored with Magnetic Resonance Imaging

M. Berger, M. Wendland, C. Mamot, 2004, Cancer Research.

Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors

G. Christofori, C. Mamot, C. Rochlitz, 2014, EJNMMI Research.

Evidence for the involvement of 5-lipoxygenase products in the regulation of the expression of the proenkephalin gene in cultured astroglial cells.

C. Mamot, T. Simmet, D. K. Meyer, 1995, Brain research. Molecular brain research.

Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99

A. Goldhirsch, J. Bernhard, B. Thürlimann, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Diffusivity changes in bevacizumab-responding and -refractory meningioma

C. Mamot, U. Roelcke, L. Remonda, 2017, Neuroradiology.

Reply to H.J.A. Adams and T.C. Kwee.

C. Mamot, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data

A. Goldhirsch, B. Thürlimann, K. Zaman, 2019, BMC Cancer.

1195OFINAL RESULTS OF THE SAKK 16/00 TRIAL: A RANDOMIZED PHASE III TRIAL COMPARING NEOADJUVANT CHEMORADIATION TO CHEMOTHERAPY ALONE IN STAGE IIIA/N2 NON-SMALL CELL LUNG CANCER (NSCLC).

R. Mirimanoff, R. Stupp, R. Stahel, 2014, Annals of Oncology.

Neoadjuvant chemotherapy with or without preoperative irradiation in stage IIIA/N2 non-small cell lung cancer (NSCLC): A randomized phase III trial by the Swiss Group for Clinical Cancer Research (SAKK trial 16/00).

R. Mirimanoff, R. Stupp, R. Stahel, 2013 .

Liposome-based approaches to overcome anticancer drug resistance.

C. Mamot, John W. Park, D. Drummond, 2003, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy

S. Barrans, C. Burton, M. Care, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multimodality Treatment in Ewing's Sarcoma Family Tumors of the Maxilla and Maxillary Sinus: Review of the Literature

C. Mamot, S. Prestin, F. Metternich, 2016, Sarcoma.

Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial

R. Mirimanoff, R. Stupp, R. Stahel, 2015, The Lancet.

Development of ligand-targeted liposomes for cancer therapy

C. Benz, C. Mamot, John W. Park, 2004, Expert opinion on therapeutic targets.

Targeting the epidermal growth factor receptor (EGFR)--a new therapeutic option in oncology?

C. Mamot, C. Rochlitz, 2006, Swiss medical weekly.

A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer

K. Zaman, R. Winterhalder, C. Mamot, 2023, Scientific Reports.

The addition of deep hyperthermia to gemcitabine-based chemoradiation may achieve enhanced survival in unresectable locally advanced adenocarcinoma of the pancreas

O. Riesterer, C. Mamot, M. Guckenberger, 2021, Clinical and translational radiation oncology.

Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study.

Andreas Wicki, Richard Herrmann, Lukas Bubendorf, 2012, The Lancet. Oncology.

Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.

Udo Greiser, C. Mamot, John W. Park, 2003, Cancer research.

A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults.

M. Weller, S. Hofer, A. Hottinger, 2020, Swiss medical weekly.

Simultaneous targeting of VEGF-receptors 2 and 3 with immunoliposomes enhances therapeutic efficacy

K. Alitalo, G. Christofori, C. Mamot, 2016, Journal of drug targeting.

First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07).

H. Moch, R. Dummer, P. Schraml, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study

C. Mamot, A. Tzankov, S. Dirnhofer, 2015, Journal of Hematology & Oncology.

Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study

L. Cascione, C. Mamot, A. Tzankov, 2022, Cancers.

Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R‐CHOP14: A SAKK 38/07 trial post‐hoc analysis

L. Cascione, C. Mamot, S. Dirnhofer, 2021, Hematological oncology.

“HEATPAC” - a phase II randomized study of concurrent thermochemoradiotherapy versus chemoradiotherapy alone in locally advanced pancreatic cancer

B. Seifert, O. Riesterer, R. Grobholz, 2017, Radiation oncology.

Targeting immunoliposomes to EGFR-positive glioblastoma

G. Hutter, C. Mamot, C. Rochlitz, 2022, ESMO open.

Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial

S. Barrans, C. Burton, R. Stephens, 2019, The Lancet. Oncology.

SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model.

L. Cascione, C. Mamot, G. Martinelli, 2020, Blood advances.

Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort

C. Mamot, A. Tzankov, S. Dirnhofer, 2017, Journal of Hematology & Oncology.

Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B‐cell lymphoma: post‐hoc analysis from the SAKK38/07 clinical trial

L. Cascione, C. Mamot, L. Ceriani, 2020, Hematological oncology.

Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up

S. Barrans, C. Burton, D. Westhead, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Decision-Making among Experts in Advanced Hodgkin Lymphoma

C. Mamot, F. Stenner, P. Putora, 2022, Oncology.

Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data

A. Goldhirsch, B. Thürlimann, K. Zaman, 2019, BMC Cancer.

Mutation Profiling of Lung Cancers with Long-Term Response to Gefitinib Therapy

C. Mamot, S. Aebi, R. Büttner, 2015, Oncology Research and Treatment.

A Prospective Randomised Trial of Targeted Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) Based upon Real-Time Gene Expression Profiling: The Remodl-B Study of the UK NCRI and SAKK Lymphoma Groups (ISRCTN51837425)

S. Barrans, M. Care, C. Mamot, 2015 .

Development of novel liposomal and receptor tyrosine kinase-targeted immunoliposomal vinorelbine formulations with improved drug retention

C. Mamot, John W. Park, J. Marks, 2005 .

Radioimmunotherapy (RIT) with 177 Lutetium-DOTA-Rituximab (177LU-D- R): A Phase I/II - Study in 30 Patients with Relapsing Follicular, Mantle Cell and Other Indolent B-Cell Lymphomas

R. Herrmann, R. Winterhalder, C. Mamot, 2008 .